Among adults with both obesity and an autoimmune disease, those taking a glucagon-like peptide-receptor 1 agonist (GLP-1RA) medication had lower rates of emergency department visits and were less likely to experience serious ...
Jun 6, 2026
0
8
Competing in esports, also known as electronic sports, can mean training for several hours a day in front of a screen. Whether people participate in video game competitions at the professional or amateur level, they face ...
May 21, 2026
0
3
Underlying cardiovascular risk, rather than older age, drives complications such as venous thromboembolism, cardiomyopathy and heart failure during pregnancy, according to new Weill Cornell Medicine research. The findings ...
May 18, 2026
0
5
Researchers at Mass General Brigham Heart and Vascular Institute and collaborators have developed and validated a new genetic risk test that can estimate a person's inherited risk for eight common cardiovascular conditions, ...
Apr 29, 2026
0
7
Older adults recovering from serious blood clots often face long periods of hospitalization or rehabilitation due to a higher rate of recurrence. But a new study suggests that the choice of blood thinner may influence how ...
Apr 27, 2026
0
5
Blood clots that form in veins—known as venous thromboembolisms—are a leading cause of illness and death worldwide. Despite the serious threat they pose to human health, researchers have never fully understood why these clots ...
Apr 20, 2026
0
6
The first clinical trial to compare two commonly used drugs head-to-head for venous thrombosis treatment has found a clear winner: while both drugs work well to prevent recurrent blood clots, apixaban is safer than rivaroxaban, ...
Mar 11, 2026
0
23
Early detection and prompt treatment of acute pulmonary embolism (PE), a sudden and potentially life‑threatening blood clot that blocks arteries in the lungs, is critical. Comprehensive recommendations for the evaluation, ...
Feb 19, 2026
0
8
Two new studies published in Anaesthesia analyzing pain and other factors connected with day surgery in the UK show that around one in eight patients having day-case surgery end up not going home and instead are admitted ...
Jan 7, 2026
0
7
The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and only subcutaneously administered therapy for patients with epidermal growth factor receptor (EGFR)-mutated ...
Dec 23, 2025
0
13
